Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT-Reference-Cited by-同舟云学术

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT

Published:2019-07-30 Issue:1 Volume:34 Page:87-99
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gilleece Maria H.^ORCID,Labopin Myriam,Savani Bipin N.^ORCID,Yakoub-Agha Ibrahim,Socié Gerard,Gedde-Dahl Tobias,Blaise Didier^ORCID,Byrne Jennifer L.^ORCID,Craddock Charles,Cornelissen Jan J.,Arcese William^ORCID,Forcade Edouard,Crawley Charles,Polge Emmanuelle,Mohty Mohamad,Nagler Arnon

Funder

This study was supported by the European Society for Blood and Bone Marrow Transplantation funded by annual subscription from the constituent transplant centres.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0527-4.pdf

Reference54 articles.

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016;129:424–47.

2. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.

3. Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol J Am Soc Clin Oncol. 2018;36:1486–97.

4. Breems DA, Van Putten WLJ, Huijgens PC, Ossenkoppele GJ, Verhoef GEG, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol J Am Soc Clin Oncol. 2005;23:1969–78.

5. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia—Even in the Era of New Treatment Modalities Still a Significant Player;Journal of Clinical Medicine;2024-03-22

2. Monitoring Measurable Residual Disease in ALL and AML;The EBMT Handbook;2024

3. Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission;Annals of Hematology;2023-06-21

5. Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience;Leukemia Research;2023-06